论文部分内容阅读
目的研究诺维苯(NVB)联合化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法80例患者分为治疗组和对照组,治疗组用NP方案,NVB25mg/m2静脉滴注,第1,8天,顺铂(DDP)50mg静脉滴注,第3,4,5天;对照组用EP方案,DDP50mg静脉滴注第1,2,3天,依托泊苷(VP16)100mg静脉滴注,第1～5天,21d为1周期,2周期为1疗程。结果治疗组有效率为42.4%,1年生存率为35%,对照组有效率为22.5%,1年生存率为31%。主要不良反应为白细胞下降和恶心呕吐,治疗组分别占82.5%和80%。治疗组静脉炎的发生率为15%,明显高于对照组。结论NVB联合DDP治疗晚期NSCLC疗效好,毒副作用可耐受,采用锁骨下静脉穿刺置管可预防发生静脉炎。
Objective To study the efficacy and toxicities of Novobenb (NVB) combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 80 patients were divided into treatment group and control group, the treatment group with NP regimen, NVB25mg / m2 intravenous drip, the first and eighth days, cisplatin (DDP) 50mg intravenous drip, 3,4,5 days; control Group with EP regimen, DDP50mg intravenous infusion of 1,2,3 days, etoposide (VP16) 100mg intravenous infusion, 1 to 5 days, 21d for 1 cycle, 2 cycles for a course of treatment. Results The effective rate of the treatment group was 42.4%, the 1-year survival rate was 35%, the control group was 22.5%, and the 1-year survival rate was 31%. The main adverse reactions were leukopenia and nausea and vomiting, with the treatment group accounting for 82.5% and 80% respectively. The incidence of phlebitis in the treatment group was 15%, which was significantly higher than that in the control group. Conclusion NVB combined with DDP in the treatment of advanced NSCLC has good curative effect and tolerable side effects. The use of subclavian vein catheterization can prevent phlebitis.